| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Departments of Thoracic Surgery [P. M. S., K. F., J. A. R.], Tumor Biology [M. C. H., S. M. C., X. Z., J. A. R.] and Pathology [J. T. M.], The University of Texas, M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, Texas 77030
We studied non-small cell lung cancers (NSCLC) from 60 patients for abnormalities in the c-erbB-2 gene. Eleven human lung cancer cell lines, including four derived from small cell lung cancer (SCLC) and seven derived from NSCLC were also examined for altered c-erbB-2 gene expression. Southern blot analysis of paired tumor and normal lung samples demonstrated that amplification of the c-erbB-2 gene is rare in NSCLC (2/60) and not restricted to adenocarcinomas. One patient showed an EcoRI restriction fragment length polymorphism for the c-erbB-2 locus. Four of four SCLC cell lines demonstrated minimal or nondetectable expression of c-erbB-2 mRNA compared to high levels of expression by seven of seven NSCLC lines. The highest expression levels were seen in four of four adenocarcinomas. We conclude that c-erbB-2 expression is different in SCLC compared to NSCLC and high expression of c-erbB-2 is consistently present in lung adenocarcinomas.
1 Recipient of a fellowship award by the Deutsche Forschungsgemeinschaft (Sch 305/1). Present address: Department of Surgery, Technical University of Munich, Klinikum rechts der Isar, 8000 Munich 80, West Germany.
2 Supported by NCI Grant CA45187-01.
3 Supported by Grants NCI CA45265-01 and ACS-CD-360, NIH Grants RR5511-23, and the Basil O'Connor Starter Scholar Research Award 5-621 from the March of Dimes Foundation.
4 Recipient of a Rosalie B. Hite Graduate Fellowship.
5 To whom requests for reprints should be addressed, at Department of Thoracic Surgery, Box 109, The University of Texas, M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030.
Received 3/ 1/89. Revised 6/ 5/89. Accepted 6/16/89.
This article has been cited by other articles:
|
|
 |
|
  A. D. Gritzapis, I. F. Voutsas, E. Lekka, N. Tsavaris, I. Missitzis, P. Sotiropoulou, S. Perez, M. Papamichail, and C. N. Baxevanis Identification of a Novel Immunogenic HLA-A*0201-Binding Epitope of HER-2/neu with Potent Antitumor Properties J. Immunol., July 1, 2008; 181(1): 146 - 154. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Meric-Bernstam and M.-C. Hung Advances in targeting human epidermal growth factor receptor-2 signaling for cancer therapy. Clin. Cancer Res., November 1, 2006; 12(21): 6326 - 6330. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Warren, K. Kani, and R. Landgraf The N-terminal Domains of Neuregulin 1 Confer Signal Attenuation J. Biol. Chem., September 15, 2006; 281(37): 27306 - 27316. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Kani, C. M. Warren, C. S. Kaddis, J. A. Loo, and R. Landgraf Oligomers of ERBB3 Have Two Distinct Interfaces That Differ in Their Sensitivity to Disruption by Heregulin J. Biol. Chem., March 4, 2005; 280(9): 8238 - 8247. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Frank, K. Hemminki, M. Wirtenberger, J. L. Bermejo, P. Bugert, R. Klaes, R. K. Schmutzler, B. Wappenschmidt, C. R. Bartram, and B. Burwinkel The rare ERBB2 variant Ile654Val is associated with an increased familial breast cancer risk Carcinogenesis, March 1, 2005; 26(3): 643 - 647. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Van Den Bossche and C. Van de Wiele Receptor Imaging in Oncology by Means of Nuclear Medicine: Current Status J. Clin. Oncol., September 1, 2004; 22(17): 3593 - 3607. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Potti, A. K. Ganti, K. Sholes, E. Langness, V. Koka, L. Horvarth, and M. Koch Effect of Pesticide Exposure on HER-2/neu Overexpression Seen in Patients with Extensive Stage Small Cell Lung Carcinoma Clin. Cancer Res., October 15, 2003; 9(13): 4872 - 4876. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.-h. B. Chen, G. A. Chernis, V. Q. Hoang, and R. Landgraf Inhibition of heregulin signaling by an aptamer that preferentially binds to the oligomeric form of human epidermal growth factor receptor-3 PNAS, August 5, 2003; 100(16): 9226 - 9231. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Brambilla, F. Fievet, M. Jeanmart, F. de Fraipont, S. Lantuejoul, V. Frappat, G. Ferretti, P.Y. Brichon, and D. Moro-Sibilot Early detection of lung cancer: role of biomarkers Eur. Respir. J., January 1, 2003; 21(39_suppl): 36S - 44s. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.-R. Pan and W.-C. Hung Nonsteroidal Anti-inflammatory Drugs Inhibit Matrix Metalloproteinase-2 via Suppression of the ERK/Sp1-mediated Transcription J. Biol. Chem., August 30, 2002; 277(36): 32775 - 32780. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. U. Goebel, M. Iwamoto, M. Raffeld, F. Gibril, W. Hou, J. Serrano, and R. T. Jensen HER-2/neu Expression and Gene Amplification in Gastrinomas: Correlations with Tumor Biology, Growth, and Aggressiveness Cancer Res., July 1, 2002; 62(13): 3702 - 3710. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Brabender, K. D. Danenberg, R. Metzger, P. M. Schneider, J. Park, D. Salonga, A. H. Holscher, and P. V. Danenberg Epidermal Growth Factor Receptor and HER2-neu mRNA Expression in Non-Small Cell Lung Cancer Is Correlated with Survival Clin. Cancer Res., July 1, 2001; 7(7): 1850 - 1855. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N.-Y. Hsu, H.-C. Ho, K.-C. Chow, T.-Y. Lin, C.-S. Shih, L.-S. Wang, and C.-M. Tsai Overexpression of Dihydrodiol Dehydrogenase as a Prognostic Marker of Non-Small Cell Lung Cancer Cancer Res., March 1, 2001; 61(6): 2727 - 2731. [Abstract] [Full Text]
|
|
|
|
|
|
W. Xia, Y.-K. Lau, H.-Z. Zhang, F.-Y. Xiao, D. A. Johnston, A.-R. Liu, L. Li, R. L. Katz, and M.-C. Hung Combination of EGFR, HER-2/neu, and HER-3 Is a Stronger Predictor for the Outcome of Oral Squamous Cell Carcinoma Than Any Individual Family Members Clin. Cancer Res., December 1, 1999; 5(12): 4164 - 4174. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. H. Pai-Scherf, J. Villa, D. Pearson, T. Watson, E. Liu, M. C. Willingham, and I. Pastan Hepatotoxicity in Cancer Patients Receiving erb-38, a Recombinant Immunotoxin That Targets the erbB2 Receptor Clin. Cancer Res., September 1, 1999; 5(9): 2311 - 2315. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. E. Shackney, C. A. Smith, A. Pollice, M. Levitt, J. A. Magovern, R. J. Wiechmann, J. Silverman, L. Sweeney, and R. J. Landreneau GENETIC EVOLUTIONARY STAGING OF EARLY NON-SMALL CELL LUNG CANCER: THE P53 -> HER-2/NEU -> ras SEQUENCE J. Thorac. Cardiovasc. Surg., August 1, 1999; 118(2): 259 - 269. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. I. Wistuba, D. Bryant, C. Behrens, S. Milchgrub, A. K. Virmani, R. Ashfaq, J. D. Minna, and A. F. Gazdar Comparison of Features of Human Lung Cancer Cell Lines and Their Corresponding Tumors Clin. Cancer Res., May 1, 1999; 5(5): 991 - 1000. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M Roland and R M Rudd Genetics and pulmonary medicine bullet 7: Somatic mutations in the development of lung cancer Thorax, November 1, 1998; 53(11): 979 - 983. [Full Text]
|
|
|
|
 |
|
 C.-C. Hsieh, K.-C. Chow, H.-J. Fahn, C.-M. Tsai, W.-Y. Li, M.-H. Huang, and L.-S. Wang Prognostic significance of HER-2/neu overexpression in stage I adenocarcinoma of lung Ann. Thorac. Surg., October 1, 1998; 66(4): 1159 - 1163. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. F. Bongiorno, R. I. Whyte, E. J. Lesser, J. H. Moore, M. B. Orringer, and D. G. Beer Alterations of K-ras, p53, and erbB-2/neu in human lung adenocarcinomas J. Thorac. Cardiovasc. Surg., February 1, 1994; 107(2): 590 - 595. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
